Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted. Lysosome lumen. Endoplasmic reticulum lumen. Note=Subcellular fractionation of transfected ovarian cancer cells reveals full-length RNASET2 in the endoplasmic reticulum fraction and the 2 smaller RNASET2 proteolytic products in the lysosome fraction. |
Domain |
PF00445 Ribonuclease T2 family |
Function |
Has ribonuclease activity, with higher activity at acidic pH. Probably is involved in lysosomal degradation of ribosomal RNA (By similarity). Probably plays a role in cellular RNA catabolism. |
Biological Process |
GO:0006401 RNA catabolic process GO:0019439 aromatic compound catabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0046700 heterocycle catabolic process GO:0090305 nucleic acid phosphodiester bond hydrolysis GO:0090501 RNA phosphodiester bond hydrolysis GO:0090502 RNA phosphodiester bond hydrolysis, endonucleolytic GO:1901361 organic cyclic compound catabolic process |
Molecular Function |
GO:0004518 nuclease activity GO:0004519 endonuclease activity GO:0004521 endoribonuclease activity GO:0004540 ribonuclease activity GO:0016892 endoribonuclease activity, producing 3'-phosphomonoesters GO:0016894 endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters GO:0033897 ribonuclease T2 activity |
Cellular Component |
GO:0005775 vacuolar lumen GO:0005788 endoplasmic reticulum lumen GO:0043202 lysosomal lumen |
KEGG | - |
Reactome |
R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6798695: Neutrophil degranulation |
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between RNASET2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between RNASET2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of RNASET2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of RNASET2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of RNASET2 in various data sets.
|
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNASET2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNASET2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNASET2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNASET2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of RNASET2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | RNASET2 |
Name | ribonuclease T2 |
Aliases | RNASE6PL; FLJ10907; bA514O12.3; ribonuclease 6 |
Chromosomal Location | 6q27 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between RNASET2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |